Table 1.

Patients characteristics by cardiovascular diseases at baseline (before and after propensity score 1:1 matching)

	Before Matching			After Matching
Variables	Mean (S.D.)		P-value	Mean (S.D.)		P-value
	With CVD (N = 406)	Without CVD (N = 1536)		With CVD (N = 394)	Without CVD (N = 394)
SU added at index	80.8%	73.6%	0.003	-	-	-
Glitazones added at index	19.2%	26.4%		-	-	-
Demographics
Age (years)	64.3 (9.2)	59.5 (10.5)	< 0.0001	64.0 (9.0)	63.9 (10.1)	0.96
Male	65.5%	51.3%	< 0.0001	65.0%	70.3%	0.11
Caucasian	98.0%	96.7%	0.17	98.0%	98.4%	0.68
Duration of diabetes (years)	6.1 (5.2)	5.6 (4.8)	0.09	6.0 (5.0)	6.1 (5.0)	0.99
Never used alcohol	27.6%	30.4%	0.29	27.9%	26.1%	0.57
Physical Activity
No regular activity	39.1%	34.6%	0.11	37.6%	39.5%	0.58
< 3 times/week	39.1%	39.7%	0.83	41.0%	36.5%	0.12
≥ 3 times/week	21.9%	25.7%	0.12	21.4%	24.0%	0.34
Country
Spain	15.8%	28.1%	< 0.0001	16.2%	15.0%	0.62
France	6.9%	8.1%	0.43	7.1%	6.9%	0.89
UK	26.6%	16.9%	< 0.0001	26.7%	26.4%	0.94
Norway	3.0%	3.4%	0.67	3.1%	4.8%	0.20
Finland	7.4%	10.7%	0.049	7.6%	10.2%	0.21
Germany	17.7%	21.4%	0.10	18.3%	19.8%	0.59
Poland	22.7%	11.5%	< 0.0001	21.1%	17.0%	0.15
Baseline Clinical Information
HbA1c (%)	8.1 (1.3)	8.0 (1.4)	0.69	8.06 (1.26)	8.05 (1.39)	0.96
With HbA1c < 6.5%	5.2%	8.3%	0.037	5.1%	7.6%	0.14
Body mass index (kg/m2)	31.7 (8.2)	31.9 (6.2)	0.60	31.7 (6.6)	31.7 (6.7)	0.94
Physician specialty
Endocrinologists/Diabetologists	40.6%	40.6%	0.99	40.6%	41.1%	0.89
General practitioners/Internists	59.4%	59.4%		59.4%	58.9%
Duration of metformin use (years)	3.0 (2.9)	2.8 (2.5)	0.15	2.9 (2.7)	2.8 (2.5)	0.60

Note: CVD: cardiovascular diseases; S.D.: standard deviation.